Evidence map›Paper›PMID 38967658›Full record

SynthesisEuropean journal of clinical pharmacology2024

Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria.

Aiping Zhao, Ke Zhang, Zhen Wang, Kaihe Ye, Zhaosi Xu, Xiao Gong, Guanghu Zhu

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aiping ZhaoSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Guilin, 541004, China.
Ke ZhangSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Guilin, 541004, China.
Zhen WangSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Guilin, 541004, China.
Kaihe YeDepartment of Biostatistics, Guangzhou Jeeyor Medical Research Co., Ltd., Guangzhou, 510000, China.
Zhaosi XuDepartment of Biostatistics, Guangzhou Jeeyor Medical Research Co., Ltd., Guangzhou, 510000, China.
Xiao GongDepartment of Biostatistics, Guangzhou Jeeyor Medical Research Co., Ltd., Guangzhou, 510000, China. x.gong@foxmail.com.
Guanghu ZhuSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Guilin, 541004, China. ghzhu@guet.edu.cn.

Funding

Natural Science Foundation of Guangxi Zhuang Autonomous Region 2024GXNSFAA010475Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region 2022AC06002
6 · The paper itself

Abstract

purposeSeveral studies have shown that subcutaneous injections of omalizumab can treat chronic idiopathic/spontaneous urticaria (CIU/CSU) patients by only assessing the efficacy on specific endpoints. This study aimed to quantitatively analyze different doses of omalizumab in CIU/CSU and compare it with ligelizumab.

methodsLiterature searches were performed in PubMed, Embase, and Web of Science databases. A model-based meta-analysis (MBMA) was utilized to develop a model incorporating time since the initiation of treatment and dose for omalizumab, with the change from baseline in Urticaria Activity Score (CFB-UAS7) as the primary efficacy endpoint. The time-course and dose-effect relationship throughout the omalizumab treatment period was analyzed, and the findings were compared with those of the investigational ligelizumab.

resultsThe model equation for the CFB-UAS7 was established as E = -E

conclusionOmalizumab showed a significant dose-dependent effect in the treatment of CSU. Both 72 mg and 120 mg ligelizumab might have the potential to outperform 150 mg (but not 300 mg) omalizumab.

Indexed as

Anti-Allergic AgentsChronic UrticariaOmalizumabAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugHumansModels, BiologicalTime FactorsTreatment OutcomeAnti-Allergic AgentsAntibodies, Monoclonal, HumanizedligelizumabOmalizumabChronic spontaneous urticariaDose-effectModel-based meta-analysisOmalizumabTime-course

Identifiers

PMID38967658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.